Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLEXERIL vs BRYNOVIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.
Brynoxin is a potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.
Adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions (FDA-approved),Off-label: Fibromyalgia, chronic muscle spasm, tension headaches, and as a sleep aid
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.
Adult: 150 mg orally twice daily.
Terminal elimination half-life is 18 hours (range 8–37 hours) with clinical context: requires dose adjustment in hepatic impairment; steady-state reached in ~3–5 days.
Terminal elimination half-life is 12 hours in patients with normal renal function; prolonged to 24-48 hours in moderate to severe renal impairment (Cr Cl < 30 m L/min).
Primarily hepatic via CYP3A4, CYP1A2, and CYP2D6; undergoes N-demethylation and glucuronidation. Active metabolite: norcyclobenzaprine.
Primarily metabolized via glucuronidation by UGT1A9 and UGT2B7; minor metabolism by CYP3A4.
Primarily hepatic; approximately 50% excreted in urine as metabolites, less than 1% unchanged; 40% excreted in feces via bile.
Renal excretion accounts for 70% of the administered dose as unchanged drug; biliary/fecal excretion accounts for 30%.
~93% bound to plasma proteins, primarily albumin.
85% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
~14 L/kg (range 10–20 L/kg), indicating extensive tissue distribution.
1.5 L/kg, indicating extensive tissue distribution and penetration into peripheral compartments.
Oral: ~33% due to extensive first-pass metabolism.
Oral: 75% (range: 60-90%) with minimal first-pass metabolism; intravenous: 100%.
No specific dosage adjustment guidelines; use with caution in renal impairment due to potential for increased side effects.
Cr Cl 30-59 m L/min: 75 mg twice daily; Cr Cl 15-29 m L/min: 50 mg twice daily; Cr Cl <15 m L/min or dialysis: 25 mg once daily.
Contraindicated in hepatic impairment; Child-Pugh class A, B, C: no safe dosage established.
Child-Pugh A: no adjustment; Child-Pugh B: 75 mg twice daily; Child-Pugh C: 50 mg twice daily.
Not recommended for use in children under 15 years old; safety and efficacy not established.
Children ≥12 years and ≥40 kg: 150 mg twice daily; <40 kg: 5 mg/kg/dose twice daily (max 150 mg/dose).
Use lower starting dose (e.g., 5 mg) and titrate slowly; increased risk of sedation and anticholinergic effects. May not be well tolerated; consider alternative therapy.
No specific dose adjustment, but monitor renal function; start at lower end of dosing range if renal impairment.
None
None.
Should not be used for longer than 2-3 weeks (acute use only),May impair mental or physical abilities required for driving or operating machinery,Central nervous system depression additive with alcohol and other CNS depressants,Anticholinergic effects: caution in patients with angle-closure glaucoma, urinary retention, or prostatic hypertrophy,Cardiovascular effects: risk of arrhythmias, especially in patients with preexisting cardiac disease (tachycardia, QT prolongation),Serotonin syndrome risk when used with MAOIs, SSRIs, SNRIs, or other serotonergic drugs,Hepatic impairment: lower doses recommended
Ketoacidosis: Monitor for signs of ketoacidosis, including euglycemic ketoacidosis,Lower limb amputation: Consider risk factors prior to initiation; monitor for signs of infection or ulceration
Concurrent use of MAOIs or within 14 days of MAOI therapy,Acute recovery phase of myocardial infarction,Arrhythmias, heart block, or congestive heart failure,Hyperthyroidism
Severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease on dialysis,History of serious hypersensitivity reaction to brynoxin or any excipient in the formulation
Alcohol should be avoided due to additive CNS depression. No specific food interactions; take with or without food. Grapefruit juice does not significantly interact, but caution with high-fat meals may alter absorption slightly.
Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition. Avoid alcohol as it may increase hepatotoxicity risk. Take with food to reduce gastrointestinal upset.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. Second trimester: no known risk. Third trimester: potential for neonatal adverse effects such as respiratory depression and withdrawal if used near term.
First trimester: Human data limited; animal studies show embryotoxicity at supra-therapeutic doses. Avoid unless benefit outweighs risk. Second trimester: No specific malformation signal; monitor fetal growth. Third trimester: Risk of neonatal adaptation syndrome (irritability, feeding difficulties) at delivery if used near term.
Excreted in breast milk in small amounts (M/P ratio not established). Clinical relevance uncertain; however, due to potential for adverse effects in nursing infants, caution is advised. Alternative therapies preferred, especially when nursing a premature or low-birth-weight infant.
Excreted in breast milk in low amounts (M/P ratio 0.2–0.4). Considered compatible with breastfeeding; monitor infant for sedation or gastrointestinal effects.
No specific dosing adjustments recommended for pregnancy. Use lowest effective dose and shortest duration due to potential neonatal effects. Pharmacokinetics may be altered in pregnancy; however, no dose adjustment guidelines exist.
Due to increased volume of distribution and enhanced hepatic clearance in second and third trimesters, the dose may need to be increased by 20–40% to maintain therapeutic plasma concentrations. Therapeutic drug monitoring (trough levels) recommended every 2 weeks with target range 5–15 mcg/m L. Postpartum: reduce dose to pre-pregnancy level within first week.
Flexeril (cyclobenzaprine) is structurally related to tricyclic antidepressants (TCAs) and shares similar anticholinergic and sedative properties. It should not be used longer than 2-3 weeks due to lack of evidence for efficacy beyond that duration. Avoid in patients with hyperthyroidism, heart block, or recent MI. Concomitant use with MAOIs can cause hypertensive crisis. Onset of muscle relaxation is delayed; therapeutic effect may not be apparent until after 2-4 days. Sedation is the most common side effect and can be used to aid sleep.
Monitor renal function and electrolytes before and during therapy. Use with caution in patients with pre-existing cardiac disease due to risk of QT prolongation. Adjust dose in hepatic impairment (Child-Pugh B or C). Contraindicated with strong CYP3A4 inducers.
Do not take for longer than 3 weeks unless directed by your doctor.,This medication may cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase sedation.,Do not stop suddenly if taken regularly; taper dose to avoid withdrawal symptoms like headache or nausea.,Inform your doctor if you have glaucoma, urinary retention, or are taking MAO inhibitors (e.g., phenelzine, tranylcypromine).,Take exactly as prescribed; do not increase dose or frequency.,May cause dry mouth; use sugar-free gum or candy for relief.
Take exactly as prescribed; do not skip doses or double up.,Avoid grapefruit and grapefruit juice during treatment.,Report any signs of infection, unusual bruising, or yellowing of skin or eyes.,Use effective contraception during treatment and for 3 months after last dose.,Do not drive if you experience dizziness or blurred vision.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLEXERIL vs BRYNOVIN, answered by our medical review team.
FLEXERIL is a Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.. BRYNOVIN is a Opioid Partial Agonist that works by Brynoxin is a potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLEXERIL and BRYNOVIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLEXERIL is: 10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.. The standard adult dose of BRYNOVIN is: Adult: 150 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLEXERIL and BRYNOVIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLEXERIL is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. . BRYNOVIN is classified as Category C. First trimester: Human data limited; animal studies show embryotoxicity at supra-therapeutic doses. Avoid unless benefit outweighs risk. Second trimester: No specific malformation . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.